Galimedix Therapeutics, Inc.

11:15 AM - 11:30 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
Phase 2 Ophthalmology and Neuroscience company developing a small molecule with unique MOA to provide neuroprotection, restore suppressed visual function, and to slow progression in dry AMD and glaucoma. Licensed from Tel Aviv University, GAL-101 has high affinity/specificity to misfolded amyloid beta, to block formation of toxic oligomers and reduce their toxicity to neural tissues. Eye drop administration reproducibly achieved >90% neuroprotection in glaucoma rat models, compelling efficacy evidence in AMD models, strong retinal delivery in monkeys, and safety in completed Phase 1 study (n=70). With a highly experienced top neuropharma team, Galimedix enjoys the support of world leading retinal and glaucoma experts. Raising funds for Phase 2 studies to demonstrate improvement of visual function in dry AMD and in glaucoma, and to develop an oral version for other indications.
Company Type:
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
GAL-101 eye drops for dry AMD and glaucoma
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Co-Founder and Chief Scientific Officer
Galimedix Therapeutics, Inc